



**NCCTG**

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** August 15, 2008

**To:** Primary Clinical Research Associates

**From:** Alicia Elsing  
Protocol Development Coordinator

**Re:** N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Due to the inclusion of central review of tissue to confirm diagnosis, the Pathology Submission Form and Pathology Reporting Form have been added to the forms packet.

If you have any questions, please feel free to contact me at 507/538-3893.

Enclosure